MLH1 Antibody - #DF3621
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# DF3621, RRID:AB_2835993.
展开/折叠
COCA 2; COCA2; DNA mismatch repair protein Mlh1; FCC 2; FCC2; hMLH 1; hMLH1; HNPCC 2; HNPCC; HNPCC2; MGC5172; MLH 1; MLH1; MLH1_HUMAN; MutL homolog 1 (E. coli); MutL homolog 1; MutL homolog 1 colon cancer nonpolyposis type 2; MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli); MutL protein homolog 1; MutL, E. coli, homolog of, 1;
抗原和靶标
Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
- P40692 MLH1_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRGEALASISHVAHVTITTKTADGKCAYRASYSDGKLKAPPKPCAGNQGTQITVEDLFYNIATRRKALKNPSEEYGKILEVVGRYSVHNAGISFSVKKQGETVADVRTLPNASTVDNIRSIFGNAVSRELIEIGCEDKTLAFKMNGYISNANYSVKKCIFLLFINHRLVESTSLRKAIETVYAAYLPKNTHPFLYLSLEISPQNVDVNVHPTKHEVHFLHEESILERVQQHIESKLLGSNSSRMYFTQTLLPGLAGPSGEMVKSTTSLTSSSTSGSSDKVYAHQMVRTDSREQKLDAFLQPLSKPLSSQPQAIVTEDKTDISSGRARQQDEEMLELPAPAEVAAKNQSLEGDTTKGTSEMSEKRGPTSSNPRKRHREDSDVEMVEDDSRKEMTAACTPRRRIINLTSVLSLQEEINEQGHEVLREMLHNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSEPAPLFDLAMLALDSPESGWTEEDGPKEGLAEYIVEFLKKKAEMLADYFSLEIDEEGNLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAMFYSIRKQYISEESTLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNILQLANLPDLYKVFERC
种属预测
score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - P40692 作为底物
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| S2 | Acetylation | Uniprot | |
| S2 | Phosphorylation | Uniprot | |
| K33 | Ubiquitination | Uniprot | |
| K57 | Ubiquitination | Uniprot | |
| K70 | Ubiquitination | Uniprot | |
| K84 | Ubiquitination | Uniprot | |
| S87 | Phosphorylation | Uniprot | |
| K123 | Ubiquitination | Uniprot | |
| K134 | Ubiquitination | Uniprot | |
| K140 | Ubiquitination | Uniprot | |
| K164 | Ubiquitination | Uniprot | |
| K167 | Ubiquitination | Uniprot | |
| K175 | Ubiquitination | Uniprot | |
| Y183 | Phosphorylation | Uniprot | |
| K196 | Ubiquitination | Uniprot | |
| T212 | Phosphorylation | Uniprot | |
| K236 | Ubiquitination | Uniprot | |
| T288 | Phosphorylation | Uniprot | |
| Y293 | Phosphorylation | Uniprot | |
| S295 | Phosphorylation | Uniprot | |
| K333 | Ubiquitination | Uniprot | |
| S370 | Phosphorylation | Uniprot | |
| K377 | Ubiquitination | Uniprot | |
| Y379 | Phosphorylation | Uniprot | |
| T386 | Phosphorylation | Uniprot | |
| S388 | Phosphorylation | Uniprot | |
| K392 | Sumoylation | Uniprot | |
| K392 | Ubiquitination | Uniprot | |
| K402 | Acetylation | Uniprot | |
| K402 | Ubiquitination | Uniprot | |
| S406 | Phosphorylation | Q13315 (ATM) , Q13535 (ATR) | Uniprot |
| K416 | Sumoylation | Uniprot | |
| K416 | Ubiquitination | Uniprot | |
| K443 | Acetylation | Uniprot | |
| K443 | Ubiquitination | Uniprot | |
| S446 | Phosphorylation | Uniprot | |
| K453 | Ubiquitination | Uniprot | |
| S459 | Phosphorylation | Uniprot | |
| K461 | Acetylation | Uniprot | |
| S467 | Phosphorylation | Uniprot | |
| S477 | Phosphorylation | Uniprot | |
| S486 | Phosphorylation | Uniprot | |
| K488 | Ubiquitination | Uniprot | |
| T495 | Phosphorylation | Uniprot | |
| S508 | Phosphorylation | Uniprot | |
| K688 | Ubiquitination | Uniprot | |
| K732 | Ubiquitination | Uniprot | |
| K751 | Ubiquitination | Uniprot |
研究背景
Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
Nucleus. Chromosome.
Note: Recruited to chromatin in a MCM9-dependent manner.
Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
Component of the DNA mismatch repair (MMR) complex composed at least of MSH2, MSH3, MSH6, PMS1 and MLH1. Heterodimer of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts with MCM9; the interaction recruits MLH1 to chromatin. Interacts MCM8. Interacts with PMS2. Interacts with MBD4. Interacts with EXO1. Interacts with MTMR15/FAN1.
Belongs to the DNA mismatch repair MutL/HexB family.
研究领域
· Genetic Information Processing > Replication and repair > Mismatch repair.
· Genetic Information Processing > Replication and repair > Fanconi anemia pathway.
· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)
限制条款
产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.